Handelen Globus Medical, Inc. - GMED CFD

Globus Medical, Inc., a medical device company, focuses on the development and commercialization of implants that heal patients with musculoskeletal disorders. Its spine product portfolio includes a range of implant and surgical approach options that can be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. In addition, it provides motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures; imaging, navigation, and robotic assisted surgery technology solutions; and hip and knee joint solutions, as well as distributes human cell, tissue, and cellular and tissue based products. Further, the company offers expandable spacer products, which include RISE, RISE-L, CALIBER, CALIBER-L, ALTERA, ELSA, ELSA-ATP, SABLE, MAGNIFY, MAGNIFY-S, FORTIFY, and XPand; CREO thoracolumbar stabilization platform that offers instruments and implants for treating pathologies; CREO MIS and CREO MCS, options designed for less invasive surgery and minimal muscle disruption; CREO Derotation and CREO Rod Link Reducer systems, which help to streamline various derotation maneuvers for deformity correction; CREO Addition that provides a range of connectors; and CREO Fenestrated, a cement augmented pedicle screw system for patients with advanced stage tumors and limited life expectancy, as well as QUARTEX, an occipito-cervico-thoracic stabilization system. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.

Nieuwste artikelen over aandelen

Palantir aandelen prognose 2021-2025
Palantir aandelen prognose 2021-2025: is er verdere stijging na de post-IPO rally?
Moet u investeren in het softwarebedrijf na zijn recente IPO? Lees verder voor Capital.com's Palantir aandelenkoers voorspelling.
06:58, 22 november 2021

Lees onze beoordelingen om meer te weten te komen

Lees de feedback van onze klanten, ongeacht hun ervaringsniveau.

Klaar om bij een toonaangevende makelaar te werken?

Word lid van onze gemeenschap van handelaars wereldwijd
1. Maak een account aan2. Maak uw eerste storting3. Ga aan de slag